Status:
COMPLETED
The Effects of Risperidone and Olanzapine on Thinking
Lead Sponsor:
US Department of Veterans Affairs
Collaborating Sponsors:
Janssen, LP
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition. Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medi...
Eligibility Criteria
Inclusion
- Diagnosed with schizophrenia disorder by a DSM IV.
- Competent to sign informed consent
- No history of poor response to Risperdal and Zyprexa
- No organic brain disease
Exclusion
- Mental retardation or any chronic medical illness which results in the patient not being appropriate for a switch to Risperdal or Zyprexa.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00108368
Start Date
October 1 2003
End Date
March 1 2006
Last Update
January 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073